December 09, 2019

What’s A Deal Worth? Benchmarking Pharma Partnering in Europe

The 2019 Benchmarking Pharma Partnering in Europe report outlines how deals are flowing in Europe, noting partnerships in this region don’t come without their costs.

A look at the risks and rewards in the European market

We analyzed 43 pharmaceutical licensing deals between January 2012 and August 2019, in which Europe was the major territory for a foreign partner.
Some of the details in the report include:

  • • Total deal size;
  • • Upfront and equity payments;
  • • Development, commercial and total milestones;
  • • Royalties;
  • • Number of products in a deal;
  • • Therapeutic area and deal value;
  • • Phase of development and deal value;

Discover if partnering in China will be worthwhile for your company.

Get the PDF:
What's a Deal Worth? Benchmarking Pharma Partnering in Europe

An extraordinary approach to effective partnering.